Back to results
US 11,230,524 B2Granted
Myocyte enhancer factor 2 (MEF2) modulators
AssigneeThe Standard Co., Ltd.
InventorJunhu Zhang
Life of this patent
Estimating the term…
Abstract
The present disclosure provides novel compounds capable of functioning as Myocyte Enhancer Factor 2 (MEF2) modulators, as well as compositions, pharmaceutical formulations, methods of synthesis and kits.
Claims6
A compound of Structure I:
- or a pharmaceutically acceptable solvate, pharmaceutically acceptable salt or pharmaceutically acceptable stereoisomer thereof, wherein:
- Y is independently selected from the group consisting of 2-aminophenyl and hydroxyl;
- X is independently selected from the group consisting of —NH—, —C(═O)NH—, —(CH2)n—NH—, —(CH2)n—NH—(CH2)n—, and —NH—(CH2)n—, wherein n is 1, 2, or 3;
- R1-R3 are each independently selected from the group consisting of hydrogen, cyclopropyloxy, halogen, ethoxy, methoxy, methyl-mercaptan, ethoxy, ethyl, cyano, isopropyloxy, cyclobutyloxy, cyclopentyloxy, 3-oxetanyloxy, morpholinyl, 4-morpholinyl, dimethylamino, butyl, pyrrolidinyl, ethylmethylamino, piperidinyl, piperazinyl, diethylamino, dimethylaminomethyl, 3-oxetanyl, 2,2-difluoroethoxy, 1,1-difluoroethyl, methylsulfide, trifluoromethylsulfide, 2,2,2-trifluoroethoxy, and trifluoroethoxy, wherein at least one or two of R1-R3 are not hydrogen;
- and
- R4-R6 are each independently selected from the group consisting of hydrogen and halogen, wherein R4 and R5 are hydrogen and R6 is a halogen.
3 more elements
A compound of Structure I:
- or a pharmaceutically acceptable solvate, pharmaceutically acceptable salt or pharmaceutically acceptable stereoisomer thereof, wherein:
- Y is independently selected from the group consisting of 2-aminophenyl and hydroxyl;
- X is independently selected from the group consisting of —NH—, —C(═O)NH—, —(CH2)n—NH—, —(CH2)n—NH—(CH2)n—, and —NH—(CH2)n—, wherein n is 1, 2, or 3;
- R1-R3 are each independently selected from the group consisting of hydrogen, cyclopropyloxy, halogen, ethoxy, methoxy, methyl-mercaptan, ethoxy, ethyl, cyano, isopropyloxy, cyclobutyloxy, cyclopentyloxy, 3-oxetanyloxy, morpholinyl, 4-morpholinyl, dimethylamino, butyl, pyrrolidinyl, ethylmethylamino, piperidinyl, piperazinyl, diethylamino, dimethylaminomethyl, 3-oxetanyl, 2,2-difluoroethoxy, 1,1-difluoroethyl, methylsulfide, trifluoromethylsulfide, 2,2,2-trifluoroethoxy, and trifluoroethoxy, wherein at least one or two of R1-R3 are not hydrogen;
- and
- R4-R6 are each independently selected from the group consisting of hydrogen and halogen, wherein R4 and R6 are hydrogen and R5 is a halogen.
3 more elements
A compound of Structure I:
- or a pharmaceutically acceptable solvate, pharmaceutically acceptable salt or pharmaceutically acceptable stereoisomer thereof, wherein:
- Y is independently selected from the group consisting of 2-aminophenyl and hydroxyl;
- X is independently selected from the group consisting of —NH—, —C(═O)NH—, —(CH2)n—NH—, —(CH2)n—NH—(CH2)n—, and —NH—(CH2)n—, wherein n is 1, 2, or 3;
- R1-R3 are each independently selected from the group consisting of hydrogen, cyclopropyloxy, halogen, ethoxy, methoxy, methyl-mercaptan, ethoxy, ethyl, cyano, isopropyloxy, cyclobutyloxy, cyclopentyloxy, 3-oxetanyloxy, morpholinyl, 4-morpholinyl, dimethylamino, butyl, pyrrolidinyl, ethylmethylamino, piperidinyl, piperazinyl, diethylamino, dimethylaminomethyl, 3-oxetanyl, 2,2-difluoroethoxy, 1,1-difluoroethyl, methylsulfide, trifluoromethylsulfide, 2,2,2-trifluoroethoxy, and trifluoroethoxy, wherein at least one or two of R1-R3 are not hydrogen;
- and
- R4-R6 are each independently selected from the group consisting of hydrogen and halogen, wherein R5 and R6 are hydrogen and R4 is a halogen.
3 more elements
Dependencies are inferred from the claim text.